Ventyx Biosciences, Inc. (VTYX)
| Market Cap | 1.00B +730.9% |
| Revenue (ttm) | n/a |
| Net Income | -106.61M |
| EPS | -1.50 |
| Shares Out | 71.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,448,870 |
| Open | 13.99 |
| Previous Close | 13.98 |
| Day's Range | 13.99 - 14.00 |
| 52-Week Range | 0.78 - 25.00 |
| Beta | 1.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 27, 2026 |
About VTYX
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn’s disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patie... [Read more]
Financial Performance
Financial StatementsNews
Ventyx Biosciences, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 29, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ventyx Biosciences, Inc., (“Ventyx" or the "Company") (NASDAQ: VTYX) investors that the firm has initiated an investigation...
Halper Sadeh LLC Encourages VTYX and SNCY Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm as there may be limited time to enforce your rights. Shareholders should contact the firm as there may be limited time to enforce your rights.
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - January 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Ventyx Biosciences, ...
Pharma stocks are set to take off this year, says UBS' Michael Yee
Michael Yee, global head of biotech research at UBS, joins CNBC's ‘Squawk on the Street' to explain why he is bullish on biopharma stocks this year, the pharma M&A outlook, and more.
Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal
Eli Lilly will buy Ventyx Biosciences in an all-cash deal worth $1.2 billion, the companies said on Wednesday, marking the Zepbound maker's latest push to expand beyond its blockbuster diabetes and we...
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on Lilly's established capabilities in inflammatory-me...
Lilly in talks to buy Ventyx Biosciences in more than $1 billion deal, WSJ reports
Eli Lilly is in advanced talks to buy Ventyx Biosciences for over $1 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.
Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion, according to people familiar with the matter
The more-than-$1 billion deal could come imminently.
Ventyx Provides Clinical and Corporate Updates
Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical Advisor Expanding the Phase 2 recurrent pericarditis study into Canada, EU and the...
Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies f...
Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London
SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies f...
Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Data from the recent Phase 2 study position Ventyx's NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease Positive topline data from Phase 2a biomar...
Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors
VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the firs...
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies f...
Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Positive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinson's disease Data from the Phase 2 study of VTX2735 in patients with recurre...
Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease
The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson's disease
Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies fo...
Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson's disease • H2 readout from VTX2735 study in patients with recurren...
Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists
Appointment of seven recognized experts is validating for Ventyx's NLRP3 Program -- AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson's disease SAN DIEGO, April 01, 2025 (GLOB...
Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress
Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2 VTX3232 in participants with obesity and cardiometabolic risk factors...
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025
Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE ...
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies f...
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio
First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a br...
Ventyx Biosciences Announces Departure of Chief Financial Officer
SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a br...